Q-omics provides the consensus-scored NEURL1B profile across patient tissues and cancer cell-line models. NEURL1B expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, NEURL1B is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, NEURL1B RNA expression shows 19,260 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, and ACC as cancer lineages where NEURL1B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NEURL1B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NEURL1B survival associations across molecular data types. NEURL1B RNA expression shows survival associations in the most cancer types (24), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NEURL1B RNA expression–survival associations across cancer types. High NEURL1B expression shows unfavorable associations in UVM, MESO, KIRP and ACC, but favorable associations in KIRC and COAD. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for NEURL1B RNA expression.
This table summarizes NEURL1B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for NEURL1B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NEURL1B shows lower tumor expression in COAD, BLCA and UCEC and higher tumor expression in KIRC, HNSC and LIHC. The KIRC box plot shows higher NEURL1B RNA expression in tumor versus normal tissue (log2 FC = +1.437, t-test p < 0.001).
This table shows molecular features associated with NEURL1B in patient tissues and cancer cell lines. In patient samples, NEURL1B shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, NEURL1B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BLOOD_Leukemia.
